Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (14316)	11/22/2004 10:06:03 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<Did I interpret correctly from the PR that they will be adjusting catheter placement for the PRECISE trial ?>> No, I did not interpret trial protocol change as you did. "In a previous poster presentation at the American Association of Neurological Surgeons (AANS) meeting in May of this year, Dr. Sampson compared the distribution of the drug when catheters were positioned according to the guidelines used in the PRECISE trial to the distribution of the drug when the positioning of the catheters did not meet these criteria. " Enrolling started slow, but it looks like they are no at 20pts/month, precisetrial.com. I do not follow NEOL or their drug candidate, but we need something new for GBM and maybe this is??? Miljenko